Transdermal dopaminergic D<sub>2</sub> receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study
J. Thomas Hutton(Hospital Clínico San Carlos), Jerry L. Morris, Peter A. LeWitt, Cheryl Waters, James P. Bennett(University of Virginia Medical Center), Ali Samii(University of Namur), Leo Verhagen Metman(Rush University Medical Center), Vincent P. Calabrese(Hunter Holmes McGuire VA Medical Center), Richard J. Barrett, Joseph Tsui(University of British Columbia), Thomas N. Chase(Encore Pharmaceuticals (United States)), Donald B. Calne(University of British Columbia), William C. Koller(Stanford University), Jorge L. Juncos(Emory University), Rajesh Pahwa(University of Kansas Medical Center)
Cited by 60
Related Papers
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Variable expression of Parkinson's disease
|Neurology|1990|1.3k
International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study
|Movement Disorders|2006|1.1k
Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease
|The American Journal of Human Genetics|2003|537